Oakview Capital Management’s Pfizer PFE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q2
Sell
-273,706
Closed -$9.92M 17
2021
Q1
$9.92M Sell
273,706
-5,196
-2% -$184K 3.61% 16
2020
Q4
$10.3M Sell
278,902
-125,033
-31% -$4.59M 4.34% 14
2020
Q3
$14.1M Sell
403,935
-709
-0.2% -$24.9K 6.14% 10
2020
Q2
$12.6M Sell
404,644
-319,615
-44% -$10.9M 5.76% 9
2020
Q1
$22.4M Buy
724,259
+97,527
+16% +$3.32M 9.86% 1
2019
Q4
$23.3M Buy
626,732
+61,774
+11% +$2.2M 8.58% 2
2019
Q3
$19.3M Sell
564,958
-14,137
-2% -$514K 6.59% 8
2019
Q2
$23.8M Sell
579,095
-17,626
-3% -$700K 7.84% 5
2019
Q1
$24M Buy
596,721
+226,390
+61% +$9.07M 7.62% 5
2018
Q4
$15.3M Sell
370,331
-252,882
-41% -$10.5M 5.69% 11
2018
Q3
$26.1M Sell
623,213
-145,982
-19% -$5.62M 9.32% 2
2018
Q2
$26.5M Sell
769,195
-84,468
-10% -$2.89M 10.59% 1
2018
Q1
$28.7M Buy
853,663
+60,517
+8% +$2.08M 11.51% 1
2017
Q4
$27.3M Buy
793,146
+91,048
+13% +$3.1M 12.13% 1
2017
Q3
$23.8M Buy
+702,098
New +$22.6M 11.33% 3
2017
Q2
Sell
-642,195
Closed -$20.8M 26
2017
Q1
$20.8M Buy
642,195
+57,847
+10% +$1.82M 9.9% 2
2016
Q4
$18M Buy
+584,348
New +$17.8M 10.16% 1

Other funds holding PFE

Oakview Capital Management's PFE Position: Q2 2021 in Review

Oakview Capital Management sold out of Pfizer (PFE) in Q2 2021, closing a stake of 273,706 shares — an estimated $9.92M sold.

Oakview Capital Management first reported a position in PFE in Q4 2016 and held it in 17 quarters. The position peaked at $28.7M in Q1 2018. 2,732 funds tracked by Wall St. Rank hold PFE as of Q2 2021.

  • Oakview Capital Management reported no remaining Pfizer position as of Q2 2021 after selling out during the quarter.
  • Oakview Capital Management sold 273,706 Pfizer shares in Q2 2021, an estimated $9.92M.
  • Oakview Capital Management first reported a position in Pfizer in Q4 2016 and held it in 17 quarters.
  • Oakview Capital Management's Pfizer position peaked at $28.7M in Q1 2018.
  • 2,732 funds tracked by Wall St. Rank held Pfizer as of Q2 2021.

Based on Oakview Capital Management's 13F filing for Q2 2021, filed 6 Aug 2021.